Latest News and Press Releases

Additional investors include global investment firm Viking Global Investors, charity foundation CureEB, the Epidermolysis Bullosa Medical Research Foundation (EBMRF), and Stanford University. The...

New York, USA, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Rare Skin Disorders Market: Key Insights into Future Outlook and Trends of Pemphigus Vulgaris, Epidermolysis Bullosa, Palmoplantar Pustulosis, and...

LifeArc and DEBRA Austria launch £2.5 million funding callfor repurposing therapies for epidermolysis bullosa New call for projects for treatments that could be repurposed to treat epidermolysis...

Burlingame, Feb. 13, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global epidermolysis bullosa market is estimated to be valued at US$ 3,429.30 million in 2022 and expected to...

Phase 2 clinical trial recently expanded to include adolescents following independent review of early safety dataFirst adolescent patient with EB enrolled into clinical trial and completed treatment...

Topline results anticipated in the fourth quarter of 2021Of the 31 patients enrolled in the trial, 29 patients completed the study with no missing visits, including the three primary endpoint...

VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare...

Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline...

Filings submitted in Austria, Israel, and Serbia for a Phase 2 Clinical Trial with INM-755 creamAdditional submissions slated for France, Germany, Greece, and Italy over the next several days and...

Los Angeles, USA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Epidermolysis bullosa pipeline anticipated to offer several novel pipeline therapies in the next decade  The Epidermolysis bullosa clinical...